Browsing Tag
Capricor Therapeutics
4 posts
Can Secretome Therapeutics turn its expanded leadership team into a Duchenne breakthrough?
Secretome Therapeutics has recruited experienced clinical, operational, medical affairs and finance executives as the private biotechnology company prepares to move STM-01 deeper into development for Duchenne muscular dystrophy-associated cardiomyopathy. The appointments indicate that Secretome is building the organisation required for late-stage trials and potential commercialisation, although the ultimate value of that infrastructure will depend on whether STM-01 produces convincing clinical evidence.
Capricor Therapeutics (NASDAQ: CAPR) reports sustained efficacy and safety in 4-year DMD trial of Deramiocel
Capricor Therapeutics reports 4-year HOPE-2 data for Deramiocel in Duchenne, showing cardiac stability and slowed muscle decline. Read how it may shape future FDA decisions.
Capricor Therapeutics advances deramiocel toward FDA approval with priority review
Capricor Therapeutics has reached a significant milestone in its efforts to develop a novel treatment for Duchenne muscular…
Capricor Therapeutics announces promising long-term results for deramiocel deramiocel in Duchenne muscular dystrophy
Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company at the forefront of developing cell and exosome-based therapies, has shared…